Long-term control of congestive heart failure with captopril

Area of Science:

• Cardiology
• Pharmacology

Background:

• Resistant congestive heart failure (CHF) poses significant therapeutic challenges.
• Angiotensin-converting enzyme (ACE) inhibitors like captopril are crucial in managing CHF.
• Understanding the long-term hemodynamic effects of captopril is essential for optimizing treatment.

Purpose of the Study:

• To assess the long-term hemodynamic effects of captopril in patients with resistant congestive heart failure.
• To identify hemodynamic markers predicting response to captopril therapy.
• To evaluate the relationship between hormonal changes and clinical response.

Main Methods:

• Sequential hemodynamic studies over six months in 19 patients with resistant CHF.
• Measurement of cardiac output, stroke volume, heart rate, total peripheral resistance, and pulmonary mean transit time.
• Analysis of plasma renin activity and aldosterone levels.

Main Results:

• Gradual hemodynamic improvement observed in most patients over three months.
• Significant reductions in total peripheral resistance and cardiopulmonary volume correlated with clinical improvement.
• Shortening of pulmonary mean transit time was a consistent indicator of response.
• Increased plasma renin activity and decreased plasma aldosterone were noted, with the aldosterone/renin ratio indicating compliance.

Conclusions:

• Captopril therapy can lead to gradual but significant improvement in resistant CHF.
• Peripheral hemodynamic changes, including reduced total peripheral resistance and cardiopulmonary volume, are key to captopril's efficacy.
• The plasma aldosterone/renin activity ratio serves as a reliable marker for patient adherence to captopril treatment.